FDA
-
-
-
-
-
-
-
Xencor Reports First Quarter 2022 Financial Results
-
-
-
-
-
-
-
Xencor Reports Fourth Quarter and Full Year 2020 Financial Results
-
-
-
-
-
-
-
Xencor Reports First Quarter 2020 Financial Results
-
-
-
-
-
-
-
Xencor Announces Partial Clinical Hold Lifted on Phase 1 Study of XmAb®14045
-
-
-
-
-
-
-
Xencor Reports First Quarter 2018 Financial Results
-
-
-
-
-
-
-
Xencor (XNCR) Announces Orphan Drug Designation from FDA for XmAb5871 to Treat IgG4-Related Disease
-
-
-
-
328,148 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

